v3.26.3
Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2018
Apr. 30, 2026
Aug. 31, 2025
Dec. 31, 2023
May 31, 2018
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue - current           $ 9,410,000   $ 9,410,000   $ 15,331,000
Deferred revenue - non-current           34,809,000   34,809,000   39,977,000
Total revenue from UT           101,870,000 $ 82,130,000 301,416,000 $ 237,011,000  
Milestone payments               521,000 639,000  
Cipla Ltd                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           0   100,000    
Collaborations and services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           19,405,000 26,506,000 77,941,000 78,727,000  
AFREZZA product sales                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           45,002,000 22,305,000 120,892,000 63,732,000  
United Therapeutics Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           56,297,000 59,288,000 178,953,000 171,563,000  
United Therapeutics Corporation | Manufacturing Services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           300,000 0 $ 2,700,000 1,200,000  
Collaboration and License Agreement | United Therapeutics Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Royalty percentage 10.00%                  
Royalty future net sales percentage       1.00%            
Royalty retaining percentage       9.00%            
License agreement description               There have been various amendments to the CSA since inception. Under the Seventh Amendment, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA    
UT License Agreement                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Upfront payment received     $ 5,000,000              
Development milestones     $ 35,000,000              
Percentage of royalty on net sales     10.00%              
Supplemental payment received   $ 5,000,000                
Deferred revenue - current           800,000   $ 800,000    
Total revenue from UT               9,200,000    
Initial upfront payment and supplemental payment           10,000,000   10,000,000    
UT License Agreement | Constrained                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Development milestones     $ 35,000,000              
Commercial Supply Agreement | United Therapeutics Corporation                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Deferred revenue           43,400,000   43,400,000   51,300,000
Deferred revenue - current           8,600,000   8,600,000   11,300,000
Deferred revenue - non-current           34,800,000   34,800,000   $ 40,000,000
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           16,526,000 25,969,000 68,139,000 77,011,000  
Co-Promotion Agreement | Amphastar                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Performance obligation transaction price recognized           500,000 500,000 1,500,000 1,500,000  
Co-Promotion Agreement | Collaborations and services | Amphastar                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT           $ 500,000 500,000 $ 1,500,000 1,500,000  
License and Distribution Agreement | Cipla Ltd                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Marketing and distribution agreement date         2018-05          
License and Distribution Agreement | Collaborations and services | Cipla Ltd                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT             37,000   110,000  
License and Distribution Agreement | Collaborations and services | India | Cipla Ltd                    
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                    
Total revenue from UT             $ 0   $ 0